ArticleDrug design, development and therapy2026
Everolimus Attenuates Salicylate-Induced Tinnitus-Like Behavior and Auditory Cortical Hyperexcitability.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tinnitus is an auditory perception without external stimuli, driven by maladaptive neuroplasticity. This study investigated whether targeting the mTOR pathway with everolimus (EVE) could ameliorate pathological synaptic marker alterations, neurochemical imbalance, and neural hypersynchrony in the primary auditory cortex (A1) using a sodium salicylate (SS)-induced acute tinnitus rat model. Methods: Adult rats were divided into Control, Tinnitus, and Tinnitus+EVE groups. Behavioral phenotypes were assessed using gap prepulse inhibition of the acoustic startle (GPIAS) test. In vivo multi-channel electrophysiology was used to measure spontaneous firing rates (SFR) and local field potentials (LFPs), focusing on gamma-band power and theta-gamma phase-amplitude coupling (PAC) in A1. Molecular changes were quantified via Western blotting, immunofluorescence, immunohistochemistry, and targeted LC-MS/MS neurotransmitter profiling. Results: Salicylate-induced tinnitus-like gap-detection deficits were mitigated by systemic EVE administration. Rats with tinnitus-like behavior displayed A1 hyperexcitability, reflected by elevated spontaneous firing rates and heightened c-Fos expression. Their network activity was disrupted, showing increased gamma-band power and significantly strengthened theta-gamma phase-amplitude coupling. At the molecular level, the mTOR pathway was activated, and the synaptic proteins BDNF and PSD95 were upregulated. Neurochemically, the excitatory neurotransmitter glutamate accumulated significantly. Everolimus administration suppressed these abnormalities, attenuating the aberrant firing rates, pathological theta-gamma coupling, and the excessive synaptic protein and glutamate levels. Conclusion: Targeted mTOR inhibition attenuates salicylate-induced tinnitus-like behavior by modulating maladaptive synaptic plasticity markers and mitigating pathological network hypersynchrony in A1. These findings suggest the mTOR cascade as a potential target for regulating cortical oscillatory and synaptic homeostasis in auditory phantom perception models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.